Drew Holzapfel is the Executive Director of the Global CEO Initiative on Alzheimer’s Disease, a coalition of leading corporations investing in Alzheimer’s disease research, treatment, and care. He is also a Partner at High Lantern Group, a healthcare consultancy focused on the intersection of business strategy and public policy. Mr. Holzapfel brings nearly two decades of healthcare experience in government and corporate affairs, sales, and marketing in global biotechnology, pharmaceutical, and U.S. government organizations to a diverse client base. He has spent over 10 years working on Alzheimer’s disease in a range of positions. Prior to joining High Lantern Group, Mr. Holzapfel was at Pfizer, where he most recently led efforts around the company’s Alzheimer’s program and advanced Alzheimer’s and aging issues through development of commercial strategy and advocacy with international organizations, nongovernmental organizations, nonprofits, and other key stakeholders.
